By Susan Brinkmann, For The Bulletin
Sunday, September 20, 2009
A new cervical cancer vaccine, dubbed the “promiscuity jab” in the UK, is responsible for more than 2,000 complaints since the government began administering it to female teens last year. The same drug is currently under consideration by the Food and Drug Adminstration (FDA) for use in the U.S.
Cervarix, manufactured by GlaxoSmithKline, competes with Merck’s more expensive Gardasil vaccine in the UK where more than a million teens have already received it as part of a government program. The new drug, which is administered in three doses, targets two HPV strains that cause cervical cancer – HPV 16 and HPV 18.
But after a year of use, the track record for Cervarix does not appear to be much better than the problem-strewn Gardasil.